On Wednesday, Larimar Therapeutics, Inc. (LRMR) stated that it had set the price for its forthcoming public offer of 17,162,472 shares at $8.74 each.
It's the company's intention to utilize the projected net proceeds of $150 million from this offering towards the development of its prospective pipeline candidates. The funds will also be utilized to supplement working capital and to support generic corporate activities.
This public offering is anticipated to be finalized around February 16, 2024.
The joint bookrunning managers for this offering are Leerink Partners, Citigroup, and Guggenheim Securities.
